As expected, the AD mice traversed platforms less frequently and the mice treated with GLP-1 or/and TRF treatment made some progress, especially the dual treatment group (p = 0.0174, AD vs. WT; p = 0.0334, AD vs. AD + GLP-1 + TRF. The gene discussed is GCG; the disease is Alzheimer disease.